# Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

> **NCT01262118** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 69 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CP-690,550 (tasocitinib)

## Key facts

- **NCT ID:** NCT01262118
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-02
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262118, "Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01262118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*